Successful adjunctive use of bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient

Introduction We describe the use of bacteriophage therapy in a 26-year-old cystic fibrosis (CF) patient awaiting lung transplantation. Hospital Course The patient developed multidrug resistant (MDR) Pseudomonas aeruginosa pneumonia, persistent respiratory failure, and colistin-induced renal failure....

Full description

Saved in:

Bibliographic Details
Published in:	Infection Vol. 47; no. 4; pp. 665 - 668
Main Authors:	Law, Nancy, Logan, Cathy, Yung, Gordon, Furr, Carrie-Lynn Langlais, Lehman, Susan M., Morales, Sandra, Rosas, Francisco, Gaidamaka, Alexander, Bilinsky, Igor, Grint, Paul, Schooley, Robert T., Aslam, Saima
Format:	Journal Article
Language:	English
Published:	Berlin/Heidelberg Springer Berlin Heidelberg 01.08.2019 Springer Nature B.V
Subjects:	Antibiotics Antiinfectives and antibacterials Antimicrobial agents Case Report Colistin Cystic fibrosis Drug resistance Family Medicine General Practice Infectious Diseases Internal Medicine Intravenous administration Lung transplantation Lung transplants Medicine Medicine & Public Health Multidrug resistance Multidrug resistant organisms Patients Pneumonia Pseudomonas aeruginosa Renal failure Respiratory failure Therapy Transplantation Multidrug-resistant Antimicrobial Cystic fibrosis Antibiotic Bacteriophage therapy Lung transplant Multidrug-resistant Pseudomonas aeruginosa
ISSN:	0300-8126, 1439-0973, 1439-0973
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	Introduction We describe the use of bacteriophage therapy in a 26-year-old cystic fibrosis (CF) patient awaiting lung transplantation. Hospital Course The patient developed multidrug resistant (MDR) Pseudomonas aeruginosa pneumonia, persistent respiratory failure, and colistin-induced renal failure. We describe the use of intravenous bacteriophage therapy (BT) along with systemic antibiotics in this patient, lack of adverse events, and clinical resolution of infection with this approach. She did not have recurrence of pseudomonal pneumonia and CF exacerbation within 100 days following the end of BT and underwent successful bilateral lung transplantation 9 months later. Conclusion Given the concern for MDR P. aeruginosa infections in CF patients, BT may offer a viable anti-infective adjunct to traditional antibiotic therapy.
AbstractList	We describe the use of bacteriophage therapy in a 26-year-old cystic fibrosis (CF) patient awaiting lung transplantation. The patient developed multidrug resistant (MDR) Pseudomonas aeruginosa pneumonia, persistent respiratory failure, and colistin-induced renal failure. We describe the use of intravenous bacteriophage therapy (BT) along with systemic antibiotics in this patient, lack of adverse events, and clinical resolution of infection with this approach. She did not have recurrence of pseudomonal pneumonia and CF exacerbation within 100 days following the end of BT and underwent successful bilateral lung transplantation 9 months later. Given the concern for MDR P. aeruginosa infections in CF patients, BT may offer a viable anti-infective adjunct to traditional antibiotic therapy. We describe the use of bacteriophage therapy in a 26-year-old cystic fibrosis (CF) patient awaiting lung transplantation.INTRODUCTIONWe describe the use of bacteriophage therapy in a 26-year-old cystic fibrosis (CF) patient awaiting lung transplantation.The patient developed multidrug resistant (MDR) Pseudomonas aeruginosa pneumonia, persistent respiratory failure, and colistin-induced renal failure. We describe the use of intravenous bacteriophage therapy (BT) along with systemic antibiotics in this patient, lack of adverse events, and clinical resolution of infection with this approach. She did not have recurrence of pseudomonal pneumonia and CF exacerbation within 100 days following the end of BT and underwent successful bilateral lung transplantation 9 months later.HOSPITAL COURSEThe patient developed multidrug resistant (MDR) Pseudomonas aeruginosa pneumonia, persistent respiratory failure, and colistin-induced renal failure. We describe the use of intravenous bacteriophage therapy (BT) along with systemic antibiotics in this patient, lack of adverse events, and clinical resolution of infection with this approach. She did not have recurrence of pseudomonal pneumonia and CF exacerbation within 100 days following the end of BT and underwent successful bilateral lung transplantation 9 months later.Given the concern for MDR P. aeruginosa infections in CF patients, BT may offer a viable anti-infective adjunct to traditional antibiotic therapy.CONCLUSIONGiven the concern for MDR P. aeruginosa infections in CF patients, BT may offer a viable anti-infective adjunct to traditional antibiotic therapy. IntroductionWe describe the use of bacteriophage therapy in a 26-year-old cystic fibrosis (CF) patient awaiting lung transplantation.Hospital CourseThe patient developed multidrug resistant (MDR) Pseudomonas aeruginosa pneumonia, persistent respiratory failure, and colistin-induced renal failure. We describe the use of intravenous bacteriophage therapy (BT) along with systemic antibiotics in this patient, lack of adverse events, and clinical resolution of infection with this approach. She did not have recurrence of pseudomonal pneumonia and CF exacerbation within 100 days following the end of BT and underwent successful bilateral lung transplantation 9 months later.ConclusionGiven the concern for MDR P. aeruginosa infections in CF patients, BT may offer a viable anti-infective adjunct to traditional antibiotic therapy. Introduction We describe the use of bacteriophage therapy in a 26-year-old cystic fibrosis (CF) patient awaiting lung transplantation. Hospital Course The patient developed multidrug resistant (MDR) Pseudomonas aeruginosa pneumonia, persistent respiratory failure, and colistin-induced renal failure. We describe the use of intravenous bacteriophage therapy (BT) along with systemic antibiotics in this patient, lack of adverse events, and clinical resolution of infection with this approach. She did not have recurrence of pseudomonal pneumonia and CF exacerbation within 100 days following the end of BT and underwent successful bilateral lung transplantation 9 months later. Conclusion Given the concern for MDR P. aeruginosa infections in CF patients, BT may offer a viable anti-infective adjunct to traditional antibiotic therapy.
Author	Furr, Carrie-Lynn Langlais Grint, Paul Schooley, Robert T. Law, Nancy Yung, Gordon Lehman, Susan M. Aslam, Saima Rosas, Francisco Morales, Sandra Gaidamaka, Alexander Bilinsky, Igor Logan, Cathy
Author_xml	– sequence: 1 givenname: Nancy orcidid: 0000-0002-2846-2691 surname: Law fullname: Law, Nancy email: nalaw@ucsd.edu organization: Division of Infectious Diseases and Global Health, University of California, San Diego – sequence: 2 givenname: Cathy surname: Logan fullname: Logan, Cathy organization: Division of Infectious Diseases and Global Health, University of California, San Diego – sequence: 3 givenname: Gordon surname: Yung fullname: Yung, Gordon organization: Division of Pulmonary, Critical Care and Sleep Medicine, University of California, San Diego – sequence: 4 givenname: Carrie-Lynn Langlais surname: Furr fullname: Furr, Carrie-Lynn Langlais organization: Ampliphi Biosciences Corporation – sequence: 5 givenname: Susan M. surname: Lehman fullname: Lehman, Susan M. organization: Ampliphi Biosciences Corporation – sequence: 6 givenname: Sandra surname: Morales fullname: Morales, Sandra organization: Ampliphi Biosciences Corporation – sequence: 7 givenname: Francisco surname: Rosas fullname: Rosas, Francisco organization: Ampliphi Biosciences Corporation – sequence: 8 givenname: Alexander surname: Gaidamaka fullname: Gaidamaka, Alexander organization: Ampliphi Biosciences Corporation – sequence: 9 givenname: Igor surname: Bilinsky fullname: Bilinsky, Igor organization: Ampliphi Biosciences Corporation – sequence: 10 givenname: Paul surname: Grint fullname: Grint, Paul organization: Ampliphi Biosciences Corporation – sequence: 11 givenname: Robert T. surname: Schooley fullname: Schooley, Robert T. organization: Division of Infectious Diseases and Global Health, University of California, San Diego, Center for Innovative Phage Applications and Therapeutics, University of California, San Diego – sequence: 12 givenname: Saima surname: Aslam fullname: Aslam, Saima organization: Division of Infectious Diseases and Global Health, University of California, San Diego, Center for Innovative Phage Applications and Therapeutics, University of California, San Diego
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/31102236$$D View this record in MEDLINE/PubMed
BookMark	eNp9kUuLFDEQx4OsuLOjX8CDBLx4ac2jn0dZfMGCgnpuqtOV2QzdyZiHMB_E72uNsyrsYQ9JiuT3r6r864pd-OCRsedSvJZCdG-SbIQUlZADLX3aH7GNrDUFQ6cv2EZoIapeqvaSXaW0F0I0Q909YZdaSqGUbjfs19diDKZky8Jh3hdvsvuJvCTkwfIJTMbowuEWdsjzLUY4HLkNkeeIkFf0-YStZclujmVXRUwuZaDrLwnLHNbgIXFAenM-JODOW6QSwVPEgZtjys5w66YYSMkPkB0lfcoeW1gSPrs7t-z7-3ffrj9WN58_fLp-e1OZupa5stpMnRQNKCughUFZo8mTrpl6DYOe0fTd0LZyaBszN1q1DdFdL5vJ9D3UoLfs1TnvIYYfBVMeV5cMLgt4DCWN5JESdaMHRejLe-g-lOipO6JU26q-JnDLXtxRZVpxHg_RrRCP41_DCVBnwNCHU0T7D5FiPE11PE91pKmOf6Y6ChL190TGZTi5mCO45WGpPksT1fE7jP_bfkD1G30muEQ
CitedBy_id	crossref_primary_10_1097_JTCCM_D_24_00022 crossref_primary_10_1016_j_imj_2025_100168 crossref_primary_10_3390_antibiotics10060672 crossref_primary_10_1016_j_ijantimicag_2025_107570 crossref_primary_10_1007_s00705_021_05173_0 crossref_primary_10_1016_j_micpath_2021_104834 crossref_primary_10_1111_ajt_15503 crossref_primary_10_3390_v13071331 crossref_primary_10_1038_s41598_024_53317_4 crossref_primary_10_5694_mja2_50355 crossref_primary_10_1038_s44259_025_00087_2 crossref_primary_10_1038_s41598_024_79924_9 crossref_primary_10_1128_spectrum_03212_23 crossref_primary_10_1089_phage_2022_0036 crossref_primary_10_3390_antibiotics10020145 crossref_primary_10_1177_20499361241307841 crossref_primary_10_1128_aac_00728_23 crossref_primary_10_3390_antibiotics13020125 crossref_primary_10_1007_s11033_024_09870_2 crossref_primary_10_1136_postgradmedj_2022_141546 crossref_primary_10_1128_cmr_00044_24 crossref_primary_10_3390_life13091835 crossref_primary_10_3390_microorganisms9030660 crossref_primary_10_1016_j_micpath_2023_106467 crossref_primary_10_1128_aac_00239_22 crossref_primary_10_3390_v16091348 crossref_primary_10_1016_j_ijantimicag_2025_107585 crossref_primary_10_1002_adma_202201210 crossref_primary_10_3390_ph16121638 crossref_primary_10_3389_fmed_2024_1432703 crossref_primary_10_1097_QCO_0000000000000658 crossref_primary_10_3390_pharmaceutics16030374 crossref_primary_10_1093_milmed_usad385 crossref_primary_10_1164_rccm_202112_2704PP crossref_primary_10_1016_j_addr_2022_114378 crossref_primary_10_1080_23744235_2024_2379492 crossref_primary_10_3390_v14010033 crossref_primary_10_1080_17425247_2021_1874343 crossref_primary_10_1021_acsabm_5c00933 crossref_primary_10_1038_s41467_025_59806_y crossref_primary_10_1093_cid_ciad528 crossref_primary_10_1002_cpt_2214 crossref_primary_10_1007_s40506_025_00287_4 crossref_primary_10_15789_2220_7619_NAF_17784 crossref_primary_10_1128_aac_01388_23 crossref_primary_10_1186_s12929_022_00806_1 crossref_primary_10_1099_jmm_0_001829 crossref_primary_10_3390_microorganisms10040717 crossref_primary_10_1183_23120541_00367_2021 crossref_primary_10_1093_ejcts_ezz295 crossref_primary_10_1093_ofid_ofaa389 crossref_primary_10_3390_ijms22042155 crossref_primary_10_1007_s40278_019_66180_1 crossref_primary_10_1038_s41467_022_29689_4 crossref_primary_10_3390_v13061182 crossref_primary_10_1183_16000617_0029_2024 crossref_primary_10_1093_g3journal_jkad210 crossref_primary_10_1016_j_drudis_2020_10_027 crossref_primary_10_1093_femsre_fuad042 crossref_primary_10_3390_ijms242115628 crossref_primary_10_1093_cid_ciad514 crossref_primary_10_1111_1462_2920_16136 crossref_primary_10_3390_microorganisms10071324 crossref_primary_10_1097_MCP_0000000000000864 crossref_primary_10_3389_fmicb_2020_593988 crossref_primary_10_1007_s00203_024_03967_9 crossref_primary_10_3390_antibiotics10060627 crossref_primary_10_1128_aac_02071_21 crossref_primary_10_3390_v13010060 crossref_primary_10_3390_v15081665 crossref_primary_10_1016_j_ijpharm_2021_121160 crossref_primary_10_3390_antibiotics10050556 crossref_primary_10_3390_antibiotics11040474 crossref_primary_10_1002_hsr2_70956 crossref_primary_10_1080_14787210_2019_1694905 crossref_primary_10_1016_j_addr_2025_115662 crossref_primary_10_1080_08927014_2021_1955866 crossref_primary_10_1183_16000617_0121_2022 crossref_primary_10_3390_microorganisms10061247 crossref_primary_10_3389_fmicb_2023_1286046 crossref_primary_10_3390_v16071051 crossref_primary_10_1016_j_ejpb_2020_11_019 crossref_primary_10_3390_v16071000 crossref_primary_10_1055_s_0042_1758728 crossref_primary_10_1038_s41467_023_39370_z crossref_primary_10_7717_peerj_15272 crossref_primary_10_1093_emph_eoaa026 crossref_primary_10_1016_j_mser_2023_100715 crossref_primary_10_1016_j_ijpharm_2024_123853 crossref_primary_10_1080_17476348_2023_2273424 crossref_primary_10_20935_AcadMolBioGen7621 crossref_primary_10_3390_ph14111157 crossref_primary_10_1016_j_cmi_2023_08_022 crossref_primary_10_3390_ijms23094577 crossref_primary_10_3390_v14091996 crossref_primary_10_1016_j_tibtech_2022_08_008 crossref_primary_10_1002_ppul_25190 crossref_primary_10_3390_ijms25158321 crossref_primary_10_3390_v13091809 crossref_primary_10_3389_fmicb_2022_907958 crossref_primary_10_1097_QCO_0000000000000627 crossref_primary_10_1128_jb_00343_24 crossref_primary_10_1097_TP_0000000000003565 crossref_primary_10_1128_msystems_00171_24 crossref_primary_10_1080_1120009X_2025_2547147 crossref_primary_10_1111_jam_15639 crossref_primary_10_3390_ijms26041755 crossref_primary_10_1080_01652176_2024_2350661 crossref_primary_10_3390_jcm12031189 crossref_primary_10_1016_j_biocontrol_2021_104678 crossref_primary_10_1128_AAC_01987_19 crossref_primary_10_1093_femsre_fuab048 crossref_primary_10_1080_17476348_2025_2517898 crossref_primary_10_1128_aem_02276_21 crossref_primary_10_3390_v13071268 crossref_primary_10_1007_s40121_022_00591_2 crossref_primary_10_3390_antibiotics12040751 crossref_primary_10_1128_mra_00953_22 crossref_primary_10_3390_ph15020186 crossref_primary_10_1038_s44259_025_00096_1 crossref_primary_10_1097_MCP_0000000000001050 crossref_primary_10_1016_j_rmed_2023_107169 crossref_primary_10_3389_fphar_2020_01096 crossref_primary_10_3390_ph14040331 crossref_primary_10_1093_jpids_piab012 crossref_primary_10_1128_spectrum_01477_23 crossref_primary_10_3389_fmicb_2020_00761 crossref_primary_10_1007_s00408_024_00700_7 crossref_primary_10_1038_s41579_022_00821_x crossref_primary_10_3390_v12050559 crossref_primary_10_1016_S1473_3099_21_00612_5 crossref_primary_10_3390_antibiotics9030135 crossref_primary_10_3390_v15020387 crossref_primary_10_1089_phage_2020_0003 crossref_primary_10_1007_s11908_020_00742_x crossref_primary_10_3389_fmicb_2021_741304 crossref_primary_10_1016_j_coviro_2022_101290 crossref_primary_10_3390_microbiolres13010002 crossref_primary_10_3390_v16060897 crossref_primary_10_3389_fmicb_2022_1052366 crossref_primary_10_1002_ppul_25091 crossref_primary_10_4167_jbv_2024_54_1_012 crossref_primary_10_1016_j_clinthera_2020_07_014 crossref_primary_10_30699_ijmm_16_1_1 crossref_primary_10_3390_antibiotics12030593 crossref_primary_10_1016_j_micpath_2023_106199 crossref_primary_10_1038_s41467_025_60598_4 crossref_primary_10_3390_antibiotics12071089 crossref_primary_10_1016_j_micpath_2024_107088 crossref_primary_10_1016_j_mimet_2021_106346 crossref_primary_10_1128_jvi_00850_23 crossref_primary_10_3390_antibiotics14050427 crossref_primary_10_3390_microorganisms11061398 crossref_primary_10_3390_microorganisms9091874 crossref_primary_10_3390_ph16101347 crossref_primary_10_1038_s41598_025_91073_1 crossref_primary_10_3390_molecules28031019 crossref_primary_10_3390_antibiotics8040182 crossref_primary_10_3390_ph16101467 crossref_primary_10_1002_phar_2358 crossref_primary_10_1016_j_prrv_2023_08_001 crossref_primary_10_1093_femsre_fuaa017 crossref_primary_10_1159_000519870 crossref_primary_10_3389_fcimb_2025_1566495 crossref_primary_10_3390_cells12010199 crossref_primary_10_3390_antibiotics10080946 crossref_primary_10_1016_j_prrv_2022_02_001 crossref_primary_10_3390_ijms24108709 crossref_primary_10_3390_ph14111162 crossref_primary_10_3389_fmicb_2021_631794 crossref_primary_10_1093_jambio_lxaf166 crossref_primary_10_1111_ans_16214 crossref_primary_10_3389_fphar_2020_569821
Cites_doi	10.1111/1469-0691.12712 10.3389/fcimb.2017.00418 10.1016/j.tibtech.2010.08.001 10.1183/09031936.00042012 10.1371/journal.pone.0060575
ContentType	Journal Article
Copyright	Springer-Verlag GmbH Germany, part of Springer Nature 2019 Infection is a copyright of Springer, (2019). All Rights Reserved.
Copyright_xml	– notice: Springer-Verlag GmbH Germany, part of Springer Nature 2019 – notice: Infection is a copyright of Springer, (2019). All Rights Reserved.
DBID	AAYXX CITATION NPM 3V. 7QL 7RV 7U9 7X7 7XB 88E 8AO 8C1 8FD 8FI 8FJ 8FK ABUWG AEUYN AFKRA BENPR C1K CCPQU FR3 FYUFA GHDGH H94 K9. KB0 M0S M1P M7N NAPCQ P64 PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS RC3 7X8
DOI	10.1007/s15010-019-01319-0
DatabaseName	CrossRef PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Nursing & Allied Health Database Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability (subscription) ProQuest Central UK/Ireland ProQuest Central Environmental Sciences and Pollution Management ProQuest One Community College Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Algology Mycology and Protozoology Abstracts (Microbiology C) ProQuest Nursing and Allied Health Premium Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China Genetics Abstracts MEDLINE - Academic
DatabaseTitle	CrossRef PubMed Technology Research Database ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest Central ProQuest One Sustainability ProQuest Health & Medical Research Collection Genetics Abstracts Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health Virology and AIDS Abstracts ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	PubMed MEDLINE - Academic Technology Research Database
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7RV name: Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1439-0973
EndPage	668
ExternalDocumentID	31102236 10_1007_s15010_019_01319_0
Genre	Journal Article
GroupedDBID	--- -53 -5E -5G -BR -EM -~C .86 .VR 04C 06C 06D 0R~ 0VY 199 1N0 203 29I 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2~H 30V 36B 4.4 406 408 409 40D 40E 53G 5GY 5RE 5VS 67Z 6NX 78A 7RV 7X7 88E 8AO 8C1 8FI 8FJ 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANZL AARTL AASML AATNV AATVU AAUYE AAWCG AAWTL AAYIU AAYQN AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABMNI ABMQK ABNWP ABPLI ABQBU ABSXP ABTEG ABTKH ABTMW ABUWG ABWNU ABXPI ACAOD ACDTI ACGFS ACHSB ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACZOJ ADHHG ADHIR ADIMF ADINQ ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEFQL AEGAL AEGNC AEJHL AEJRE AEMSY AENEX AEOHA AEPYU AESKC AETLH AEUYN AEVLU AEXYK AFBBN AFEXP AFKRA AFLOW AFQWF AFRAH AFWTZ AFZKB AGAYW AGDGC AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHKAY AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BDATZ BENPR BGNMA BKEYQ BPHCQ BSONS BVXVI CAG CCPQU CS3 CSCUP DDRTE DL5 DNIVK DPUIP DU5 EBD EBLON EBS EIHBH EIOEI EJD EMB EMOBN ESBYG EX3 F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GXS HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF IJ- IKXTQ IMOTQ ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KPH LAS LLZTM M1P M4Y MA- N9A NAPCQ NB0 NPVJJ NQJWS NU0 O93 O9G O9I O9J OAM P19 P9S PCD PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R89 R9I RHV RNS ROL RPX RRX RSV S16 S27 S37 S3B SAP SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UOJIU UTJUX VC2 W23 W48 WJK WK8 WOW YLTOR Z45 Z7U Z82 Z87 Z8O Z8V Z91 ZMTXR ZOVNA ~EX ~KM -Y2 .GJ 1SB 28- 2P1 2VQ 3O- 5QI AANXM AAPKM AARHV AAYTO AAYXX ABBRH ABDBE ABFSG ABQSL ABRTQ ABULA ACBXY ACSTC ACUDM ADHKG AEBTG AEFIE AEKMD AEZWR AFDZB AFFHD AFHIU AFOHR AGGDS AGQPQ AHPBZ AHWEU AIXLP AJBLW ATHPR AYFIA BBWZM CITATION COF EN4 GRRUI H13 HZ~ IHE KOW N2Q NDZJH O9- PHGZM PHGZT PJZUB PPXIY R4E RNI RZK S1Z S26 S28 SCLPG SDE T16 UZXMN VFIZW Y6R ZGI NPM 3V. 7QL 7U9 7XB 8FD 8FK C1K FR3 H94 K9. M7N P64 PKEHL PQEST PQUKI PRINS RC3 7X8 PUEGO
ID	FETCH-LOGICAL-c441t-f3cb7105a2f0a6a92fc315075b83a93dec879661965cd532657107815bc88a4a3
IEDL.DBID	RSV
ISICitedReferencesCount	186
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000477012200018&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0300-8126 1439-0973
IngestDate	Fri Sep 05 12:53:59 EDT 2025 Tue Nov 04 23:31:37 EST 2025 Thu Apr 03 06:54:51 EDT 2025 Sat Nov 29 06:39:04 EST 2025 Tue Nov 18 22:28:56 EST 2025 Fri Feb 21 02:32:55 EST 2025
IsPeerReviewed	true
IsScholarly	true
Issue	4
Keywords	Multidrug-resistant Antimicrobial Cystic fibrosis Antibiotic Bacteriophage therapy Lung transplant Multidrug-resistant Pseudomonas aeruginosa
Language	English
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c441t-f3cb7105a2f0a6a92fc315075b83a93dec879661965cd532657107815bc88a4a3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Case Study-2 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3
ORCID	0000-0002-2846-2691
PMID	31102236
PQID	2226628445
PQPubID	29907
PageCount	4
ParticipantIDs	proquest_miscellaneous_2232045392 proquest_journals_2226628445 pubmed_primary_31102236 crossref_primary_10_1007_s15010_019_01319_0 crossref_citationtrail_10_1007_s15010_019_01319_0 springer_journals_10_1007_s15010_019_01319_0
PublicationCentury	2000
PublicationDate	2019-08-01
PublicationDateYYYYMMDD	2019-08-01
PublicationDate_xml	– month: 08 year: 2019 text: 2019-08-01 day: 01
PublicationDecade	2010
PublicationPlace	Berlin/Heidelberg
PublicationPlace_xml	– name: Berlin/Heidelberg – name: Germany – name: New York
PublicationSubtitle	A Journal of Infectious Diseases
PublicationTitle	Infection
PublicationTitleAbbrev	Infection
PublicationTitleAlternate	Infection
PublicationYear	2019
Publisher	Springer Berlin Heidelberg Springer Nature B.V
Publisher_xml	– name: Springer Berlin Heidelberg – name: Springer Nature B.V
References	Hraiech, Bregeon, Rolain (CR3) 2015; 9 Kutateladze, Adamia (CR6) 2010; 28 Hurley, Camara, Smyth (CR2) 2012; 40 Saussereau, Vachier, Chiron (CR5) 2014; 20 Fong, Drilling, Morales (CR1) 2017; 7 Essoh, Blouin, Loukou (CR4) 2013; 8 SA Fong (1319_CR1) 2017; 7 MN Hurley (1319_CR2) 2012; 40 E Saussereau (1319_CR5) 2014; 20 M Kutateladze (1319_CR6) 2010; 28 S Hraiech (1319_CR3) 2015; 9 C Essoh (1319_CR4) 2013; 8
References_xml	– volume: 20 start-page: O983 year: 2014 end-page: O990 ident: CR5 article-title: Effectiveness of bacteriophages in the sputum of cystic fibrosis patients publication-title: Clin Microbiol Infect doi: 10.1111/1469-0691.12712 – volume: 7 start-page: 418 year: 2017 ident: CR1 article-title: Activity of bacteriophages in removing biofilms of isolates from chronic rhinosinusitis patients publication-title: Front Cell Infect Microbiol doi: 10.3389/fcimb.2017.00418 – volume: 28 start-page: 591 year: 2010 end-page: 595 ident: CR6 article-title: Bacteriophages as potential new therapeutics to replace or supplement antibiotics publication-title: Trends Biotechnol doi: 10.1016/j.tibtech.2010.08.001 – volume: 40 start-page: 1014 year: 2012 end-page: 1023 ident: CR2 article-title: Novel approaches to the treatment of infections in cystic fibrosis publication-title: Eur Respir J doi: 10.1183/09031936.00042012 – volume: 9 start-page: 3653 year: 2015 end-page: 3663 ident: CR3 article-title: Bacteriophage-based therapy in cystic fibrosis-associated infections: rationale and current status publication-title: Drug Des Dev Ther – volume: 8 start-page: e60575 year: 2013 ident: CR4 article-title: The susceptibility of strains from cystic fibrosis patients to bacteriophages publication-title: PLoS ONE doi: 10.1371/journal.pone.0060575 – volume: 8 start-page: e60575 year: 2013 ident: 1319_CR4 publication-title: PLoS ONE doi: 10.1371/journal.pone.0060575 – volume: 7 start-page: 418 year: 2017 ident: 1319_CR1 publication-title: Front Cell Infect Microbiol doi: 10.3389/fcimb.2017.00418 – volume: 9 start-page: 3653 year: 2015 ident: 1319_CR3 publication-title: Drug Des Dev Ther – volume: 28 start-page: 591 year: 2010 ident: 1319_CR6 publication-title: Trends Biotechnol doi: 10.1016/j.tibtech.2010.08.001 – volume: 40 start-page: 1014 year: 2012 ident: 1319_CR2 publication-title: Eur Respir J doi: 10.1183/09031936.00042012 – volume: 20 start-page: O983 year: 2014 ident: 1319_CR5 publication-title: Clin Microbiol Infect doi: 10.1111/1469-0691.12712
SSID	ssj0005947
Score	2.603173
Snippet	Introduction We describe the use of bacteriophage therapy in a 26-year-old cystic fibrosis (CF) patient awaiting lung transplantation. Hospital Course The... We describe the use of bacteriophage therapy in a 26-year-old cystic fibrosis (CF) patient awaiting lung transplantation. The patient developed multidrug... IntroductionWe describe the use of bacteriophage therapy in a 26-year-old cystic fibrosis (CF) patient awaiting lung transplantation.Hospital CourseThe patient... We describe the use of bacteriophage therapy in a 26-year-old cystic fibrosis (CF) patient awaiting lung transplantation.INTRODUCTIONWe describe the use of...
SourceID	proquest pubmed crossref springer
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	665
SubjectTerms	Antibiotics Antiinfectives and antibacterials Antimicrobial agents Case Report Colistin Cystic fibrosis Drug resistance Family Medicine General Practice Infectious Diseases Internal Medicine Intravenous administration Lung transplantation Lung transplants Medicine Medicine & Public Health Multidrug resistance Multidrug resistant organisms Patients Pneumonia Pseudomonas aeruginosa Renal failure Respiratory failure Therapy Transplantation
SummonAdditionalLinks	– databaseName: Health & Medical Collection dbid: 7X7 link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR3bSt1AcLAqpS_e2trjpazgm4Ym2Vw2TyKi-KIIVThvYbLZtBZJjicnBT-k_-vMZnMOIvXFt5CdTQZmdi47N4BDpbLKSN_3ItK1HmkoOlJFGnikXDMZoSoSjXbYRHp9rcbj7MZduLUurXKQiVZQl43mO_IfpMeShGRpFJ9MHj2eGsXRVTdC4wOs8Nhs5vN0nC5SPDI7YMxnXEiRJa5opi-di20YmEt4AlvI81IxvbI2X0VKrQK6WH8v6huw5kxPcdrzyiYsmXoLPl654Ppn-Pezs9MTq-5BYPmHFB6LQtG1RjSVKPq2zs3kN0kg0ZdtPQkyecU8V53BbIJiOe1-eeTHs21Kr29a05UNYYGtQENr93XTohjywGp6Eij0E7eMFhX57w3tFK7j6xe4uzi_Pbv03NQGTxO5Z14lNRHbjzGsfEwwCyst2eqMCyUxk6XRKiUfizsZ6jIm6zEm6FQFcaGVwgjlV1ium9p8A5GgLJWKMEoxi_wqLLjsQGKkQs1ubDKCYCBZrl1Lc56s8ZAvmjEzmXMic27JnPsjOJrvmfQNPd6E3htImrvD3eYLeo7gYL5Mx5JjLVibpmMYyY3-yfocwXbPQfPfyYDdbEnoHw8stfj4_3HZeRuXXfgUWnbm5MQ9WJ5NO7MPq_rv7L6dfrcH4xkOgBJN priority: 102 providerName: ProQuest
Title	Successful adjunctive use of bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient
URI	https://link.springer.com/article/10.1007/s15010-019-01319-0 https://www.ncbi.nlm.nih.gov/pubmed/31102236 https://www.proquest.com/docview/2226628445 https://www.proquest.com/docview/2232045392
Volume	47
WOSCitedRecordID	wos000477012200018&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1439-0973 dateEnd: 20241214 omitProxy: false ssIdentifier: ssj0005947 issn: 0300-8126 databaseCode: 7RV dateStart: 19970101 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1439-0973 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0005947 issn: 0300-8126 databaseCode: RSV dateStart: 19970101 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dT9wwDLcGTIgX2AaDY-yUSXvbKrVNP9JHQKC97HTiS_dWuWkKTKhF1ysSfwj_L3ba3mniQ4KXqGqcNkqc2JbtnwF-KpUURrquE5CsdUhC0ZHKYs8h4ZrIAFUWabTFJuLRSE0mybhLCqv7aPfeJWlv6kWyW2gdt5x049nUmyVYCRlthm3004tFYEdiy4q5PAMSX1GXKvP8N_4XR090zCf-USt2jjfeN-FPsN6pmWK_5YvP8MGUX2D1b-dI34SH08ZWSiyaG4H5PxJufO2JpjaiKkTWQjhXt1d024g2RetekHor5nHpTGaDEfNpc-mQzc56KL0e16bJK-JtrAUa6rsuqxpFH_NV0pNAoe8ZHloUZKtXNFJ06K5bcH58dHb4x-kqNDiatnbmFFLTxroh-oWLESZ-oSVrmGGmJCYyN1rFZE8xaqHOQ9IUQ6KOlRdmWikMUH6F5bIqzQ6ICGWuVIBBjEngFn7GKQYSA-VrNlmjAXj9RqW6gy_nKho36QJ4mdc7pfVO7Xqn7gB-zcfctuAdr1Lv9fufdge5Tkl9iiIS4UE4gB_zbjqC7FfB0lQN00gG9SdNcwDbLd_Mfyc9NqklTf93zySLj788l923kX-DNd_yGQcm7sHybNqY7_BR382u6-kQluKTC24nsW0VterQG8LKwdFofDK0x-cRORwNbw
linkProvider	Springer Nature
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VgigX3o-FAkaCE0QkcR7OASFUqFq1XVWiSL2FiePQRVWyrDeg_SH8DX4jM06yC6rorQduUew4E_ubh-N5ADxXKquM9H0vIl3rkYYilirSwCPlmskIVZFodMUm0vFYHR9nh2vwa4iFYbfKQSY6QV02mv-RvyY9liQkS6P47fSbx1Wj-HR1KKHRwWLPLH7Qls2-2X1P6_siDLc_HG3teH1VAU8TOXOvkpqI8WMMKx8TzMJKS7aK4kJJzGRptEppD8CZ9nQZk3UTU-9UBXGhlcIIJY17CS5HMpTMRWrrD5eSzBU08_nbSXEmfZBOF6oXu2NnDhkKXODQ34rwjHV75mTWKbztG__bVN2E671pLd51vHAL1kx9G64e9M4Dd-Dnx9ZVh6zaU4HlV1LoLOpFa41oKlF0aaub6QlJWNGFpS0EmfRi6YvP3ZwDZjlrv3gzY9n2ptuH1rRlQ1-NVqChtkndWBSDn1tNVwKFXnBKbFFNClqPiRV9Rtu78OlCJuUerNdNbR6ASFCWSkUYpZhFfhUWHFYhMVKh5m16MoJggEiu-5TtXDnkNF8lm2ZY5QSr3MEq90fwcvnMtEtYcm7vzQFCeS-8bL7CzwieLZtJ7PBZEtamabmP5EIGZF2P4H6H2OXrZMC_ESSR_2qA8Grwf9Py8HxansLGztHBfr6_O957BNdCx0rsiLkJ6_NZax7DFf19PrGzJ44pBXy-aGj_BkZobHM
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VLaq4UN5dKGAkOEHUJM7DOSAEtCuqwmrFQ-otdRwHFlXJst6A9of0z_DrmHGcXaGK3nrgFiVOMnE-zze25wHwVIis0tz3vQi51kOGwiFVpIGH5JrxSIoiUdIWm0jHY3F8nE024HcfC0Nulb1OtIq6bBStke8hjyUJ6tIo3qucW8Rkf_Rq9sOjClK009qX0-ggcqSXv3D6Zl4e7uO_fhaGo4PPb995rsKAp1C0hVdxhYL5sQwrXyYyCyvFyUKKC8FlxkutRIrzAcq6p8oYLZ0YW6ciiAslhIwkx-degc2U46RnAJtvDsaTj2sHk8yWN_OpJ5BGExey0wXuxXYTmgKIAhtG9DctnrN1z-3TWvobbf_PHXcDrjujm73uRslN2ND1Ldj64NwKbsPZp9bWjUTJmSy_I9UTCbDWaNZUrOgSWjezb6h7WRewtmRo7LOVlz41s66Z5bz96s21IascT0-MbssGv1oaJjVem9aNkaz3gKvxiEmmlpQsm1XTAv_N1DCX6_YOfLmUTrkLg7qp9Q6wRPJSiEhGqcwivwoLCrjgMhKhogl8MoSgh0uuXDJ3qilymq_TUBPEcoRYbiGW-0N4vrpn1qUyubD1bg-n3Kk1k6-xNIQnq8uokGiXSda6aakNpxIHaHcP4V6H3tXreEALDBzFf9HDef3wf8ty_2JZHsMWIjp_fzg-egDXQjuqyENzFwaLeasfwlX1czE180duhDI4uWxs_wFa63bR
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Successful+adjunctive+use+of+bacteriophage+therapy+for+treatment+of+multidrug-resistant+Pseudomonas+aeruginosa+infection+in+a+cystic+fibrosis+patient&rft.jtitle=Infection&rft.au=Law%2C+Nancy&rft.au=Logan%2C+Cathy&rft.au=Yung%2C+Gordon&rft.au=Furr%2C+Carrie-Lynn+Langlais&rft.date=2019-08-01&rft.pub=Springer+Berlin+Heidelberg&rft.issn=0300-8126&rft.eissn=1439-0973&rft.volume=47&rft.issue=4&rft.spage=665&rft.epage=668&rft_id=info:doi/10.1007%2Fs15010-019-01319-0&rft.externalDocID=10_1007_s15010_019_01319_0
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0300-8126&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0300-8126&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0300-8126&client=summon